Tags

Type your tag names separated by a space and hit enter

Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.
Drug Saf. 2009; 32(5):359-78.DS

Abstract

Moxifloxacin, a fluoroquinolone with potent activity against respiratory pathogens, is approved and considered as an alternative to beta-lactams and macrolides for the treatment of acute bacterial sinusitis and lower respiratory tract infections. In this review, we critically examine its safety profile in comparison with other fluoroquinolones and other antibacterial classes sharing similar indications. Data were extracted from published clinical trials, meta-analyses, postmarketing studies, spontaneous report systems and case reports for rare effects. Global analysis did not reveal significantly higher incidences of drug-related adverse effects than for comparators. Tendon rupture was infrequent with moxifloxacin, including when used in elderly patients with chronic obstructive pulmonary disease. Severe toxic cutaneous reactions and allergies were very rare. Phototoxicity and CNS adverse effects were less common than with other fluoroquinolones. Although causing a 4-7 msec corrected QT interval prolongation, severe cardiac toxicity was neither seen in large cohorts or clinical trials nor reported to pharmacovigilance systems. Hepatotoxicity was not different from what was observed for other fluoroquinolones (excluding trovafloxacin) and less frequent than reported for amoxicillin-clavulanic acid or telithromycin. The data show that using moxifloxacin, in its accepted indications and following the corresponding guidelines, should not be associated with an excessive incidence of drug-related adverse reactions, provided the clinician takes care in identifying patients with known risk factors and pays due attention to the contraindications and warnings mentioned in the labelling.

Authors+Show Affiliations

Unité de pharmacologie cellulaire et moléculaire & Centre de Pharmacie Clinique, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium. francoise.vanbambeke@uclouvain.beNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

19419232

Citation

Van Bambeke, Françoise, and Paul M. Tulkens. "Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin: Comparison With Other Fluoroquinolones and Other Antibacterial Classes." Drug Safety, vol. 32, no. 5, 2009, pp. 359-78.
Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf. 2009;32(5):359-78.
Van Bambeke, F., & Tulkens, P. M. (2009). Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Safety, 32(5), 359-78. https://doi.org/10.2165/00002018-200932050-00001
Van Bambeke F, Tulkens PM. Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin: Comparison With Other Fluoroquinolones and Other Antibacterial Classes. Drug Saf. 2009;32(5):359-78. PubMed PMID: 19419232.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. AU - Van Bambeke,Françoise, AU - Tulkens,Paul M, PY - 2009/5/8/entrez PY - 2009/5/8/pubmed PY - 2009/7/11/medline SP - 359 EP - 78 JF - Drug safety JO - Drug Saf VL - 32 IS - 5 N2 - Moxifloxacin, a fluoroquinolone with potent activity against respiratory pathogens, is approved and considered as an alternative to beta-lactams and macrolides for the treatment of acute bacterial sinusitis and lower respiratory tract infections. In this review, we critically examine its safety profile in comparison with other fluoroquinolones and other antibacterial classes sharing similar indications. Data were extracted from published clinical trials, meta-analyses, postmarketing studies, spontaneous report systems and case reports for rare effects. Global analysis did not reveal significantly higher incidences of drug-related adverse effects than for comparators. Tendon rupture was infrequent with moxifloxacin, including when used in elderly patients with chronic obstructive pulmonary disease. Severe toxic cutaneous reactions and allergies were very rare. Phototoxicity and CNS adverse effects were less common than with other fluoroquinolones. Although causing a 4-7 msec corrected QT interval prolongation, severe cardiac toxicity was neither seen in large cohorts or clinical trials nor reported to pharmacovigilance systems. Hepatotoxicity was not different from what was observed for other fluoroquinolones (excluding trovafloxacin) and less frequent than reported for amoxicillin-clavulanic acid or telithromycin. The data show that using moxifloxacin, in its accepted indications and following the corresponding guidelines, should not be associated with an excessive incidence of drug-related adverse reactions, provided the clinician takes care in identifying patients with known risk factors and pays due attention to the contraindications and warnings mentioned in the labelling. SN - 0114-5916 UR - https://www.unboundmedicine.com/medline/citation/19419232/Safety_profile_of_the_respiratory_fluoroquinolone_moxifloxacin:_comparison_with_other_fluoroquinolones_and_other_antibacterial_classes_ L2 - https://dx.doi.org/10.2165/00002018-200932050-00001 DB - PRIME DP - Unbound Medicine ER -